Binge Eating Disorder Triggers and Treatments

Binge Eating Disorder: Understanding What Drives It and How to Treat It

Dr. Tracey Marks, a psychiatrist with a talent for making mental health topics accessible, has built a video with over 306,000 views on binge eating disorder (BED). This is the most common eating disorder in the United States, affecting roughly 3% of adults, and it is directly relevant to the GLP-1 conversation because many people seeking these medications have undiagnosed or untreated BED. Dr. Marks walks through the clinical definition of BED, its triggers, and the evidence-based treatments available, providing a foundation that helps viewers understand whether their relationship with food goes beyond normal overeating.

The clinical definition of BED is specific: recurrent episodes of eating significantly more than most people would eat in a similar time period, accompanied by a sense of loss of control, and marked distress afterward. Unlike bulimia, BED does not involve purging or compensatory behaviors. The episodes happen at least once a week for three months to meet diagnostic criteria. Dr. Marks emphasizes that BED is not the same as occasionally overeating at a holiday meal or stress-eating after a bad day. It is a pattern of behavior that causes significant emotional distress and often physical consequences, including weight gain that leads people to seek GLP-1 medications without ever addressing the underlying disorder.

Triggers and the Brain Chemistry Behind Them

Dr. Marks breaks down the common triggers for binge episodes into several categories. Emotional triggers include stress, loneliness, boredom, anger, and sadness. Dietary triggers include restriction and deprivation, which is why rigid dieting often backfires for people with BED. Environmental triggers include food availability, social eating situations, and food-related cues in the environment. And neurological triggers include disrupted serotonin and dopamine signaling that makes the brain seek food as a source of neurochemical reward.

The neuroscience angle is particularly relevant for understanding how GLP-1 drugs interact with BED. Semaglutide acts on some of the same brain circuits that drive binge eating, particularly the reward and satiety pathways. This is why some patients with BED report that GLP-1 drugs dramatically reduce their binge episodes. The drug is not treating BED directly, but it is modulating the brain chemistry that makes binging feel compelling. Whether this pharmacological effect is sufficient without behavioral therapy is an open question, and Dr. Marks would likely argue that addressing the emotional and psychological triggers is still necessary even when medication reduces the neurochemical drive to binge.

What the Video Gets Right

Dr. Marks provides an accurate, destigmatizing explanation of BED that aligns with current psychiatric diagnostic criteria. She correctly distinguishes BED from emotional overeating and from other eating disorders. Her explanation of triggers is thorough and includes the restriction-binge cycle, which is one of the most misunderstood aspects of BED (many people try to treat binge eating by restricting food, which actually makes it worse). She also discusses evidence-based treatments including cognitive behavioral therapy (CBT), interpersonal therapy, and medications like lisdexamfetamine (Vyvanse), which is the only FDA-approved medication for BED.

What the Video Misses

The video was made before GLP-1 drugs became widely recognized as affecting binge eating behavior, so it does not discuss semaglutide or tirzepatide in the context of BED. This is a significant gap given how many BED patients are now being prescribed these drugs, sometimes without a formal BED diagnosis. The video also does not address the intersection of BED with weight stigma in healthcare, where patients seeking help for binge eating are often told to diet, which reinforces the restriction-binge cycle. A section on how to find a provider who understands BED and does not default to weight-focused advice would be valuable.

Questions to Bring to Your Doctor

If you think you might have BED, bring these questions to a psychiatrist or therapist who specializes in eating disorders. Do my eating patterns meet the criteria for binge eating disorder? If so, what treatment approach do you recommend: therapy, medication, or both? If I am on a GLP-1 drug, how does that change the treatment plan for BED? Should I see an eating disorder specialist in addition to my prescriber? And how do I avoid the restriction-binge cycle while also managing my weight?

BED Screening Should Be Standard Before GLP-1 Prescribing

One of the most important implications of Dr. Marks presentation for the GLP-1 audience is that BED screening should be a standard part of the pre-prescribing evaluation for weight loss medications. Currently, most GLP-1 prescriptions are written after a brief clinical encounter focused on BMI, metabolic health markers, and insurance coverage. The question of whether the patient has an eating disorder is rarely asked. This is a missed opportunity because the treatment approach for someone with BED and obesity should differ from the approach for someone with obesity alone. Both patients benefit from GLP-1 medication, but the BED patient also needs behavioral therapy, and ideally the two treatments should start simultaneously rather than waiting until the medication has been started and the eating disorder has been left unaddressed.

Screening for BED can be done quickly with validated instruments like the Binge Eating Scale or the Eating Disorder Examination Questionnaire. These take less than five minutes to complete and can be integrated into an intake form before the first appointment. If the screen is positive, the prescriber can refer the patient to a therapist who specializes in eating disorders while also starting the GLP-1 medication. This parallel approach gives the patient the best chance of both losing weight and developing a healthier relationship with food, which together produce the most sustainable long-term outcomes.

For patients who are already on a GLP-1 drug and suspect they might have BED, it is never too late to get screened and start treatment. The therapeutic window that the medication creates, with reduced cravings and less food noise, actually makes eating disorder therapy more productive because the patient can focus on the psychological work without being in the grip of active binge urges. If anything, starting therapy while on the medication is easier than waiting until after the medication is stopped, when the return of intense cravings can make behavioral change feel overwhelming and undermine the progress made during the treatment period.

The Restriction-Binge Cycle and Why Dieting Makes BED Worse

One of Dr. Marks most important points is about the restriction-binge cycle, and it deserves extra emphasis because it is so frequently misunderstood. Many people with BED try to treat their binge eating by restricting food, whether through rigid dieting, fasting, or simply trying to eat as little as possible between binge episodes. This approach feels logical on the surface: if you are eating too much, eat less. But for people with BED, restriction reliably triggers more intense and more frequent binge episodes. The biology is straightforward. When you restrict calories severely, your body interprets the restriction as a threat and responds by increasing hunger hormones, heightening food reward sensitivity, and reducing impulse control. The binge is the biological response to the restriction. Telling a person with BED to diet is like telling a person with insomnia to try harder to fall asleep. The trying itself makes the problem worse.

GLP-1 drugs are interesting in this context because they reduce caloric intake without the psychological experience of restriction. You eat less, but you do not feel deprived because your appetite is genuinely reduced rather than being overridden by willpower. This distinction matters for BED patients because it means the drug-mediated caloric reduction may not trigger the same restriction-binge cycle that voluntary dieting does. Preliminary evidence supports this. Some BED patients on GLP-1 drugs report that their binge episodes decrease dramatically without the compensatory increase in binge urges that dieting always produced. If this pattern holds up in formal clinical trials, it would make GLP-1 drugs a uniquely suitable tool for BED patients because they address both the excess caloric intake and the neurological drivers of binge behavior without triggering the restriction-binge feedback loop.

However, this is not a reason to skip therapy. Even if the medication reduces binge frequency, the emotional triggers, the distorted thinking patterns, and the disrupted relationship with food that characterize BED do not resolve on their own. The medication creates breathing room, but the therapeutic work is what creates lasting change. The combination of GLP-1 medication and evidence-based therapy for BED is likely to produce better outcomes than either approach alone, and patients who can access both should pursue both simultaneously rather than treating them as sequential options.

Who Should Watch This

This video is essential viewing for anyone who suspects they have binge eating disorder or who has been told they simply need to "eat less and exercise more" when the real issue is a compulsive eating pattern. If you are considering or already using a GLP-1 drug for weight loss and find that your eating patterns include episodes of loss-of-control eating, watching this video will help you understand whether there is a treatable condition underneath the weight issue. Therapists and prescribers who work with weight loss patients should also watch it, since BED screening should be part of the standard assessment before prescribing GLP-1 drugs. Family members and partners will find it useful for understanding what their loved one is experiencing.

BED is one of the most underdiagnosed conditions in the weight loss space, and treating the eating disorder alongside the weight is likely to produce much better long-term outcomes than medication alone.